Skip to content

Remimazolam besylate for sedation in painless gastroscop

Sequential determination of initial loading dose ED50/ED95 of remimazolam besylate combined with alfentanil for painless gastroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060354
Enrollment
Unknown
Registered
2022-05-29
Start date
2022-05-16
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation during painless gastroscop

Interventions

None listed

Sponsors

Anhui Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The patient is 18-65 years old; 2. Patients diagnosed and treated by painless gastroscopy who passed the anesthesia outpatient assessment; 3. ASA grade I-III; 4. Patients voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with bradycardia (HR <= 50 beats/min) and severe arrhythmia; 2. Combined with unstable angina and myocardial infarction; 3. Uncontrolled hypertension, diabetes, hyperthyroidism; 4. Mental system diseases (such as schizophrenia, depression, etc.), history of epilepsy and cognitive dysfunction; 5. Those who have a history of psychotropic drug and narcotic drug abuse; 6. Those with abnormal liver function, kidney function and blood coagulation function; 7. Pregnant or lactating women; 8. People who are allergic to benzodiazepines.

Design outcomes

Primary

MeasureTime frame
Sedative effect score;

Secondary

MeasureTime frame
Time of effect of sedation;Awakening time;Observation time;The occurrence of adverse reactions; MAP, HR, SPO2 at different time points;

Countries

China

Contacts

Public ContactWang Pingjuan

Anhui Second People's Hospital

1034541904@qq.com+86 13655606997

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026